Peter A. Milligan

1.8k total citations
23 papers, 1.3k citations indexed

About

Peter A. Milligan is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Pharmacology. According to data from OpenAlex, Peter A. Milligan has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Peter A. Milligan's work include Pharmacogenetics and Drug Metabolism (4 papers), Antifungal resistance and susceptibility (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Peter A. Milligan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Antifungal resistance and susceptibility (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Peter A. Milligan collaborates with scholars based in United Kingdom, United States and Sweden. Peter A. Milligan's co-authors include Mats O. Karlsson, Irja Lutsar, Antonio Arrieta, Timothy Driscoll, Thomas J. Walsh, Nolan Wood, R L Lalonde, Ulrika Wählby, Thomas Kerbusch and Peter C. Adamson and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and Toxicological Sciences.

In The Last Decade

Peter A. Milligan

23 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter A. Milligan United Kingdom	12	498	399	244	209	161	23	1.3k
Goonaseelan Pillai South Africa	15	324 0.7×	206 0.5×	103 0.4×	159 0.8×	170 1.1×	36	1.0k
Farkad Ezzet Switzerland	19	381 0.8×	270 0.7×	100 0.4×	182 0.9×	120 0.7×	27	1.7k
Martin Bergstrand Sweden	17	315 0.6×	340 0.9×	175 0.7×	487 2.3×	311 1.9×	38	2.5k
Flora T. Musuamba Belgium	22	176 0.4×	324 0.8×	90 0.4×	292 1.4×	232 1.4×	48	1.8k
MO Karlsson Sweden	17	206 0.4×	152 0.4×	148 0.6×	242 1.2×	203 1.3×	29	1.2k
Nitin Mehrotra United States	22	256 0.5×	130 0.3×	122 0.5×	166 0.8×	360 2.2×	59	1.8k
Dong‐Seok Yim South Korea	21	192 0.4×	202 0.5×	78 0.3×	262 1.3×	322 2.0×	112	1.3k
Ene Ette United States	24	252 0.5×	200 0.5×	375 1.5×	436 2.1×	321 2.0×	68	2.1k
Margo Heath‐Chiozzi United States	13	852 1.7×	265 0.7×	68 0.3×	64 0.3×	175 1.1×	22	1.7k
DR Mould United States	7	117 0.2×	158 0.4×	225 0.9×	287 1.4×	240 1.5×	7	1.5k

Countries citing papers authored by Peter A. Milligan

Since Specialization

Citations

This map shows the geographic impact of Peter A. Milligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. Milligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. Milligan more than expected).

Fields of papers citing papers by Peter A. Milligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter A. Milligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. Milligan. The network helps show where Peter A. Milligan may publish in the future.

Co-authorship network of co-authors of Peter A. Milligan

This figure shows the co-authorship network connecting the top 25 collaborators of Peter A. Milligan. A scholar is included among the top collaborators of Peter A. Milligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter A. Milligan. Peter A. Milligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Milligan, Peter A., et al.. (2023). Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1577–1590. 10 indexed citations

Blomberg, Erik J., et al.. (2022). PATHOGEN SURVEY AND PREDICTORS OF LYMPHOPROLIFERATIVE DISEASE VIRUS INFECTION IN WILD TURKEYS (MELEAGRIS GALLOPAVO). Journal of Wildlife Diseases. 58(3). 537–549. 7 indexed citations

Claret, Laurent, Jenny Zheng, François Mercier, et al.. (2016). Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy and Pharmacology. 78(3). 605–610. 4 indexed citations

Slejko, Julia F., Richard J. Willke, Jakob Ribbing, & Peter A. Milligan. (2016). Translating Pharmacometrics to a Pharmacoeconomic Model of COPD. Value in Health. 19(8). 1026–1032. 11 indexed citations

Ribbing, Jakob, et al.. (2015). Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1-A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials. Journal of Pharmacokinetics and Pharmacodynamics. 42. 2 indexed citations

Claret, Laurent, François Mercier, Brett E. Houk, Peter A. Milligan, & René Bruno. (2015). Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemotherapy and Pharmacology. 76(3). 567–573. 20 indexed citations

Milligan, Peter A., B Marchant, Steven W. Martin, et al.. (2013). Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development. Clinical Pharmacology & Therapeutics. 93(6). 502–514. 174 indexed citations

Amantea, Michael, et al.. (2012). PKPD Modeling of Predictors for Side Effects and Overall Survival in Sunitinb Treated Patients with Gastro Intestinal Stromal Tumor. 1 indexed citations

Walsh, Thomas J., Timothy Driscoll, Peter A. Milligan, et al.. (2010). Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrobial Agents and Chemotherapy. 54(10). 4116–4123. 100 indexed citations

10.

Johnson, Trevor N., Thomas Kerbusch, Barry Jones, et al.. (2009). Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: usingin vitrodata as an aid to assess study power. Pharmaceutical Statistics. 8(3). 186–202. 11 indexed citations

11.

Agoram, Balaji, Peter A. Milligan, & Piet H. van der Graaf. (2008). A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: Application to inhaled bronchodilators. European Journal of Pharmaceutical Sciences. 34(4-5). 250–256. 7 indexed citations

12.

Karlsson, Mats O., Irja Lutsar, & Peter A. Milligan. (2008). Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies. Antimicrobial Agents and Chemotherapy. 53(3). 935–944. 165 indexed citations

13.

Lalonde, R L, Karey Kowalski, Matt Hutmacher, et al.. (2007). Model-based Drug Development. Clinical Pharmacology & Therapeutics. 82(1). 21–32. 300 indexed citations

14.

Wise, John Pierce, et al.. (2007). Ku80 Deficiency Does Not Affect Particulate Chromate-Induced Chromosome Damage and Cytotoxicity in Chinese Hamster Ovary Cells. Toxicological Sciences. 97(2). 348–354. 11 indexed citations

15.

Wählby, Ulrika, Alison H. Thomson, Peter A. Milligan, & Mats O. Karlsson. (2004). Models for time‐varying covariates in population pharmacokinetic‐pharmacodynamic analysis. British Journal of Clinical Pharmacology. 58(4). 367–377. 56 indexed citations

16.

Kerbusch, Thomas, Peter A. Milligan, & Mats O. Karlsson. (2003). Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data. British Journal of Clinical Pharmacology. 57(2). 170–180. 25 indexed citations

17.

Kerbusch, Thomas, Ulrika Wählby, Peter A. Milligan, & Mats O. Karlsson. (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailability. British Journal of Clinical Pharmacology. 56(6). 639–652. 42 indexed citations

18.

Milligan, Peter A., Scott Marshall, & Mats O. Karlsson. (2002). A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. British Journal of Clinical Pharmacology. 53(s1). 45S–52S. 55 indexed citations

19.

Milligan, Peter A., Peter McGill, Colin W. Howden, A. W. Kelman, & B. Whiting. (1993). The consequences of H2 receptor antagonist ? piroxicam coadministration in patients with joint disorders. European Journal of Clinical Pharmacology. 45(6). 507–512. 5 indexed citations

20.

Milligan, Peter A.. (1992). Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 576(1). 121–128. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact